InterpaceBiosciences_New Logo.png
Interpace Biosciences Announces Record Second Quarter 2023 Financial and Business Results
August 09, 2023 12:30 ET | Interpace Biosciences, Inc.
 ●Q2 Revenue of $11.0 million; a 49% increase year-over-year; highest quarter in history ●Q2 Test volume up 15% year over year to record levels ●Q2 Reimbursement improvement up 34% year-over-year...
InterpaceBiosciences_New Logo.png
Interpace Biosciences Announces Update of Previously Announced CMS Billing Policy Impacting its Thyroid Tests
February 22, 2022 09:00 ET | Interpace Biosciences, Inc.
PARSIPPANY, NJ, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace” or the “Company”), a leader in enabling personalized medicine, announced today that the...
InterpaceBiosciences_New Logo.png
Interpace Biosciences Announces Improved Coverage for ThyGeNEXT® and ThyraMIR®
May 03, 2021 08:00 ET | Interpace Biosciences, Inc.
Parsippany, NJ, May 03, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today that eviCore Healthcare (“eviCore”), a wholly owned...
InterpaceBiosciences_New Logo.png
Interpace Biosciences Raises Full Year 2021 Revenue Guidance
April 19, 2021 07:05 ET | Interpace Biosciences, Inc.
Parsippany, NJ, April 19, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced an update to its full year 2021 revenue guidance...
LOGO.jpg
Interpace Biosciences to Host Third Quarter 2020 Financial Results Conference Call on Thursday, January 21, 2021
January 20, 2021 15:38 ET | Interpace Biosciences, Inc.
PARSIPPANY, NJ, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) announced today that it will hold its third quarter 2020 financial results conference call and webcast...
LOGO.jpg
Interpace Biosciences Receives Nasdaq Deficiency Notice Due to Delayed Filing of Form 10-Q; No Immediate Impact on Listing
August 20, 2020 08:30 ET | Interpace Biosciences, Inc.
PARSIPPANY, NJ, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (NASDAQ: IDXG) on August 18, 2020 received notice from the Listing Qualifications Staff...
CM-slider-logo-2x.png
Checkmate Capital Invests in Community Eco Power
September 18, 2019 09:00 ET | Checkmate Capital
LOS ANGELES, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Checkmate Capital has completed an investment in Community Eco Power (CEP), a leader in the waste-to-energy industry headquartered in Asheville, North...
Q2Earth-logo.jpg
Q2Earth Signs Services Agreement in Connection with Acquisition of Two Waste-to-Energy Plants in New England
May 21, 2019 08:30 ET | Q2Earth, Inc
Palm Beach, FL, May 21, 2019 (GLOBE NEWSWIRE) -- Q2Earth, Inc. (OTCQB: QPWR) (the “Company” or “Q2”) has signed a services agreement to oversee the operational, legal and financial closing of the...
IDXG Logo.jpg
Interpace Diagnostics Labs Receive College of American Pathology (CAP) Accreditation
April 25, 2019 06:55 ET | Interpace Diagnostics Group, Inc.
Pennsylvania and Connecticut Labs Both Receive Accreditation PARSIPPANY, NJ, April 25, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it has...
IDXG Logo.jpg
Interpace Diagnostics Announces Preliminary 2018 Revenues
February 28, 2019 06:55 ET | Interpace Diagnostics Group, Inc.
Interpace to Host Fourth Quarter and Full Year 2018 Results Conference Call/Webcast PARSIPPANY, NJ, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG)...